Skip to main content
Book cover

Design and Implementation of the Modern Men’s Health Center pp 93–126Cite as

Evaluation and Management of Erectile Dysfunction

  • 228 Accesses

Abstract

Erectile dysfunction is an extremely prevalent medical condition among adult men. The causes of erectile dysfunction can be multifactorial, which necessitates a systemic approach to both diagnosing and treating this disease. In this chapter, we will discuss the intricacies that physicians should be aware of when evaluating and managing patients who present with erectile dysfunction.

Keywords

  • Erectile dysfunction
  • ED
  • Men’s health
  • Sexual medicine
  • PDE5 inhibitors
  • Intracavernosal injections
  • Penile prosthesis surgery

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-030-54482-9_6
  • Chapter length: 34 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   89.00
Price excludes VAT (USA)
  • ISBN: 978-3-030-54482-9
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   119.99
Price excludes VAT (USA)
Hardcover Book
USD   169.99
Price excludes VAT (USA)
Learn about institutional subscriptions
Fig. 6.1
Fig. 6.2
Fig. 6.3
Fig. 6.4

References

  1. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54.

    CrossRef  CAS  PubMed  Google Scholar 

  2. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84:50.

    CrossRef  CAS  PubMed  Google Scholar 

  3. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007;120:151.

    CrossRef  PubMed  Google Scholar 

  4. Lewis RW, Fugl-Meyer KS, Corona G, et al. Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med. 2010;7:1598.

    CrossRef  PubMed  Google Scholar 

  5. Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163:460.

    CrossRef  CAS  PubMed  Google Scholar 

  6. Wessells H, Joyce GF, Wise M, et al. Erectile dysfunction. J Urol. 2007;177:1675.

    CrossRef  PubMed  Google Scholar 

  7. Francis ME, Kusek JW, Nyberg LM, et al. The contribution of common medical conditions and drug exposures to erectile dysfunction in adult males. J Urol. 2007;178:591.

    CrossRef  PubMed  Google Scholar 

  8. Lue TF. A patient’s goal-directed approach to erectile dysfunction and Peyronie’s disease. Can J Urol. 1995;2:13.

    CAS  PubMed  Google Scholar 

  9. Tiefer L, Schuetz-Mueller D. Psychological issues in diagnosis and treatment of erectile disorders. Urol Clin North Am. 1995;22:767.

    CrossRef  CAS  PubMed  Google Scholar 

  10. Albaugh J, Amargo I, Capelson R, et al. Health care clinicians in sexual health medicine: focus on erectile dysfunction. Urol Nurs. 2002;22:217.

    PubMed  Google Scholar 

  11. Althof SE, Rosen RC, Perelman MA, et al. Standard operating procedures for taking a sexual history. J Sex Med. 2013;10:26.

    CrossRef  PubMed  Google Scholar 

  12. Hartmann U, Burkart M. Erectile dysfunctions in patient-physician communication: optimized strategies for addressing sexual issues and the benefit of using a patient questionnaire. J Sex Med. 2007;4:38.

    CrossRef  PubMed  Google Scholar 

  13. DeBusk R, Drory Y, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol. 2000;86:62F.

    CrossRef  CAS  PubMed  Google Scholar 

  14. Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87:766.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  15. Partin AW, Wein AJ, Kavoussi LR, et al. Campbell-Walsh urology E-book. Philadelphia: Elsevier Health Sciences; 2015.

    Google Scholar 

  16. Atiemo HO, Szostak MJ, Sklar GN. Salvage of sildenafil failures referred from primary care physicians. J Urol. 2003;170:2356.

    CrossRef  PubMed  Google Scholar 

  17. Jiann BP, Yu CC, Su CC, et al. Rechallenge prior sildenafil nonresponders. Int J Impot Res. 2004;16:64.

    CrossRef  CAS  PubMed  Google Scholar 

  18. Hatzichristou D, Moysidis K, Apostolidis A, et al. Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders. Eur Urol. 2005;47:518.

    CrossRef  PubMed  Google Scholar 

  19. Gruenwald I, Shenfeld O, Chen J, et al. Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. Eur Urol. 2006;50:134.

    CrossRef  PubMed  CAS  Google Scholar 

  20. Derogatis LR, Melisaratos N. The DSFI: a multidimensional measure of sexual functioning. J Sex Marital Ther. 1979;5:244.

    CrossRef  CAS  PubMed  Google Scholar 

  21. Rust J, Golombok S. The GRISS: a psychometric instrument for the assessment of sexual dysfunction. Arch Sex Behav. 1986;15:157.

    CrossRef  CAS  PubMed  Google Scholar 

  22. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822.

    CrossRef  CAS  PubMed  Google Scholar 

  23. O’Leary MP, Fowler FJ, Lenderking WR, et al. A brief male sexual function inventory for urology. Urology. 1995;46:697.

    CrossRef  PubMed  Google Scholar 

  24. Mulhall JP, Goldstein I, Bushmakin AG, et al. Validation of the erection hardness score. J Sex Med. 2007;4:1626.

    CrossRef  PubMed  Google Scholar 

  25. Rosen RC, Catania J, Pollack L, et al. Male Sexual Health Questionnaire (MSHQ): scale development and psychometric validation. Urology. 2004;64:777.

    CrossRef  PubMed  Google Scholar 

  26. Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319.

    CrossRef  CAS  PubMed  Google Scholar 

  27. Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200:633.

    CrossRef  PubMed  Google Scholar 

  28. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123.

    CrossRef  CAS  PubMed  Google Scholar 

  29. Brambilla DJ, Matsumoto AM, Araujo AB, et al. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab. 2009;94:907.

    CrossRef  CAS  PubMed  Google Scholar 

  30. Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168:829.

    CrossRef  CAS  PubMed  Google Scholar 

  31. La J, Roberts NH, Yafi FA. Diet and Men’s sexual health. Sex Med Rev. 2018;6:54.

    CrossRef  PubMed  Google Scholar 

  32. Salas-Salvado J, Bullo M, Babio N, et al. Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial. Diabetes Care. 2011;34:14.

    CrossRef  PubMed  Google Scholar 

  33. Trichopoulou A, Costacou T, Bamia C, et al. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med. 2003;348:2599.

    CrossRef  PubMed  Google Scholar 

  34. Eleazu C, Obianuju N, Eleazu K, et al. The role of dietary polyphenols in the management of erectile dysfunction-mechanisms of action. Biomed Pharmacother. 2017;88:644.

    CrossRef  CAS  PubMed  Google Scholar 

  35. Althof SE, Leiblum SR, Chevret-Measson M, et al. Psychological and interpersonal dimensions of sexual function and dysfunction. J Sex Med. 2005;2:793.

    CrossRef  PubMed  Google Scholar 

  36. Stravynski A, Gaudette G, Lesage A, et al. The treatment of sexually dysfunctional men without partners: a controlled study of three behavioural group approaches. Br J Psychiatry. 1997;170:338.

    CrossRef  CAS  PubMed  Google Scholar 

  37. Althof SE. When an erection alone is not enough: biopsychosocial obstacles to lovemaking. Int J Impot Res. 2002;14 Suppl 1:S99.

    CrossRef  CAS  PubMed  Google Scholar 

  38. Hawton K. Integration of treatments for male erectile dysfunction. Lancet. 1998;351:7.

    CrossRef  CAS  PubMed  Google Scholar 

  39. Rajfer J, Aronson WJ, Bush PA, et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med. 1992;326:90.

    CrossRef  CAS  PubMed  Google Scholar 

  40. Kim N, Azadzoi KM, Goldstein I, et al. A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J Clin Invest. 1991;88:112.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  41. Burnett AL. Phosphodiesterase 5 mechanisms and therapeutic applications. Am J Cardiol. 2005;96:29M.

    CrossRef  CAS  PubMed  Google Scholar 

  42. Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int. 2005;96:257.

    CrossRef  CAS  PubMed  Google Scholar 

  43. Hellstrom WJ. Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors. Int J Clin Pract. 2007;61:1547.

    CrossRef  CAS  PubMed  Google Scholar 

  44. Bruzziches R, Francomano D, Gareri P, et al. An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opin Pharmacother. 2013;14:1333.

    CrossRef  CAS  PubMed  Google Scholar 

  45. Guay AT. Optimizing response to phosphodiesterase therapy: impact of risk-factor management. J Androl. 2003;24:S59.

    CrossRef  PubMed  Google Scholar 

  46. Kedia GT, Uckert S, Assadi-Pour F, et al. Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties. Ther Adv Urol. 2013;5:35.

    CrossRef  PubMed  PubMed Central  CAS  Google Scholar 

  47. Mittleman MA, Maclure M, Glasser DB. Evaluation of acute risk for myocardial infarction in men treated with sildenafil citrate. Am J Cardiol. 2005;96:443.

    CrossRef  CAS  PubMed  Google Scholar 

  48. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol. 1999;33:273.

    CrossRef  CAS  PubMed  Google Scholar 

  49. Liu W, Antonelli PJ, Dahm P, et al. Risk of sudden sensorineural hearing loss in adults using phosphodiesterase type 5 inhibitors: population-based cohort study. Pharmacoepidemiol Drug Saf. 2018;27:587.

    CrossRef  CAS  PubMed  Google Scholar 

  50. Porst H, Burnett A, Brock G, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10:130.

    CrossRef  CAS  PubMed  Google Scholar 

  51. Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol. 2004;172:1935.

    CrossRef  PubMed  Google Scholar 

  52. MacDiarmid SA, Hill LA, Volinn W, et al. Lack of pharmacodynamic interaction of silodosin, a highly selective alpha1a-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men. Urology. 2010;75:520.

    CrossRef  PubMed  Google Scholar 

  53. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374:611.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  54. Buvat J, Montorsi F, Maggi M, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med. 2011;8:284.

    CrossRef  CAS  PubMed  Google Scholar 

  55. Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol. 1998;159:433.

    CrossRef  CAS  PubMed  Google Scholar 

  56. Teloken C, Rhoden EL, Sogari P, et al. Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. J Urol. 1998;159:122.

    CrossRef  CAS  PubMed  Google Scholar 

  57. Montorsi F, Strambi LF, Guazzoni G, et al. Effect of yohimbine-trazodone on psychogenic impotence: a randomized, double-blind, placebo-controlled study. Urology. 1994;44:732.

    CrossRef  CAS  PubMed  Google Scholar 

  58. Krzastek SC, Bopp J, Smith RP, et al. Recent advances in the understanding and management of erectile dysfunction [version 1; peer reviewL 2 approved]. F1000Res. 2019;8:102.

    CrossRef  CAS  Google Scholar 

  59. Ribe N, Rajmil O, Bassas L, et al. Response to intracavernous administration of 3 different drugs in the same group of patients with erectile dysfunction. Arch Esp Urol. 2001;54:355.

    CAS  PubMed  Google Scholar 

  60. Sharlip ID. Evaluation and nonsurgical management of erectile dysfunction. Urol Clin North Am. 1998;25:647.

    CrossRef  CAS  PubMed  Google Scholar 

  61. Wolfson B, Pickett S, Scott NE, et al. Intraurethral prostaglandin E-2 cream: a possible alternative treatment for erectile dysfunction. Urology. 1993;42:73.

    CrossRef  CAS  PubMed  Google Scholar 

  62. Williams G, Abbou CC, Amar ET, et al. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group. Br J Urol. 1998;81:889.

    CrossRef  PubMed  Google Scholar 

  63. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med. 1997;336:1.

    CrossRef  CAS  PubMed  Google Scholar 

  64. Shokeir AA, Alserafi MA, Mutabagani H. Intracavernosal versus intraurethral alprostadil: a prospective randomized study. BJU Int. 1999;83:812.

    CrossRef  CAS  PubMed  Google Scholar 

  65. Shabsigh R, Padma-Nathan H, Gittleman M, et al. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study. Urology. 2000;55:109.

    CrossRef  CAS  PubMed  Google Scholar 

  66. McVary KT, McVary KT. Contemporary treatment of erectile dysfunction: a clinical guide. New York: Humana Press; 2011.

    CrossRef  Google Scholar 

  67. Small RG, Reed J. Bleeding during dacryocystorhinostomy: the importance of the suction cautery. Arch Ophthalmol. 1990;108:638.

    CrossRef  CAS  PubMed  Google Scholar 

  68. Hellstrom WJ, Montague DK, Moncada I, et al. Implants, mechanical devices, and vascular surgery for erectile dysfunction. J Sex Med. 2010;7:501.

    CrossRef  PubMed  Google Scholar 

  69. Canguven O, Bailen J, Fredriksson W, et al. Combination of vacuum erection device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction. J Sex Med. 2009;6:2561.

    CrossRef  PubMed  Google Scholar 

  70. Chen J, Sofer M, Kaver I, et al. Concomitant use of sildenafil and a vacuum entrapment device for the treatment of erectile dysfunction. J Urol. 2004;171:292.

    CrossRef  PubMed  Google Scholar 

  71. Sun L, Peng FL, Yu ZL, et al. Combined sildenafil with vacuum erection device therapy in the management of diabetic men with erectile dysfunction after failure of first-line sildenafil monotherapy. Int J Urol. 2014;21:1263.

    CrossRef  CAS  PubMed  Google Scholar 

  72. Chen J, Godschalk MF, Katz PG, et al. Combining intracavernous injection and external vacuum as treatment for erectile dysfunction. J Urol. 1995;153:1476.

    CrossRef  CAS  PubMed  Google Scholar 

  73. John H, Lehmann K, Hauri D. Intraurethral prostaglandin improves quality of vacuum erection therapy. Eur Urol. 1996;29:224.

    CAS  PubMed  Google Scholar 

  74. Marmar JL, DeBenedictis TJ, Praiss DE. The use of a vacuum constrictor device to augment a partial erection following an intracavernous injection. J Urol. 1988;140:975.

    CrossRef  CAS  PubMed  Google Scholar 

  75. Limoge JP, Olins E, Henderson D, et al. Minimally invasive therapies in the treatment of erectile dysfunction in anticoagulated cases: a study of satisfaction and safety. J Urol. 1996;155:1276.

    CrossRef  CAS  PubMed  Google Scholar 

  76. Owen JA, Saunders F, Harris C, et al. Topical nitroglycerin: a potential treatment for impotence. J Urol. 1989;141:546.

    CrossRef  CAS  PubMed  Google Scholar 

  77. Sonksen J, Biering-Sorensen F. Transcutaneous nitroglycerin in the treatment of erectile dysfunction in spinal cord injured. Paraplegia. 1992;30:554.

    CAS  PubMed  Google Scholar 

  78. Kim ED, el-Rashidy R, McVary KT. Papaverine topical gel for treatment of erectile dysfunction. J Urol. 1995;153:361.

    CrossRef  CAS  PubMed  Google Scholar 

  79. Goldstein I, Payton TR, Schechter PJ. A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunction. Urology. 2001;57:301.

    CrossRef  CAS  PubMed  Google Scholar 

  80. Padma-Nathan H, Steidle C, Salem S, et al. The efficacy and safety of a topical alprostadil cream, Alprox-TD, for the treatment of erectile dysfunction: two phase 2 studies in mild-to-moderate and severe ED. Int J Impot Res. 2003;15:10.

    CrossRef  CAS  PubMed  Google Scholar 

  81. Rooney M, Pfister W, Mahoney M, et al. Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction. J Sex Med. 2009;6:520.

    CrossRef  CAS  PubMed  Google Scholar 

  82. Schanz S, Hauck EW, Schmelz HU, et al. Topical treatment of erectile dysfunction with prostaglandin E(1) ethyl ester. J Dtsch Dermatol Ges. 2009;7:1055.

    PubMed  Google Scholar 

  83. Le B, Burnett AL. Evolution of penile prosthetic devices. Korean J Urol. 2015;56:179.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  84. Garber BB. Inflatable penile prostheses for the treatment of erectile dysfunction: an update. Expert Rev Med Devices. 2008;5:133.

    CrossRef  PubMed  Google Scholar 

  85. Jarow JP, Nana-Sinkam P, Sabbagh M, et al. Outcome analysis of goal directed therapy for impotence. J Urol. 1996;155:1609.

    CrossRef  CAS  PubMed  Google Scholar 

  86. Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie’s disease: AUA guideline. J Urol. 2015;194:745.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  87. Jain S, Terry TR. Penile prosthetic surgery and its role in the treatment of end-stage erectile dysfunction – an update. Ann R Coll Surg Engl. 2006;88:343.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  88. Mulcahy JJ, Wilson SK. Current use of penile implants in erectile dysfunction. Curr Urol Rep. 2006;7:485.

    CrossRef  PubMed  Google Scholar 

  89. Bettocchi C, Palumbo F, Spilotros M, et al. Penile prostheses. Ther Adv Urol. 2010;2:35.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  90. Anderson PC, Jain S, Summerton DJ, et al. Surgical atlas. Insertion of an inflatable penile prosthesis. BJU Int. 2007;99:467.

    CrossRef  PubMed  Google Scholar 

  91. Wang R, Howard GE, Hoang A, et al. Prospective and long-term evaluation of erect penile length obtained with inflatable penile prosthesis to that induced by intracavernosal injection. Asian J Androl. 2009;11:411.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  92. Wosnitzer MS, Greenfield JM. Antibiotic patterns with inflatable penile prosthesis insertion. J Sex Med. 2011;8:1521.

    CrossRef  PubMed  Google Scholar 

  93. Jarow JP. Risk factors for penile prosthetic infection. J Urol. 1996;156:402.

    CrossRef  CAS  PubMed  Google Scholar 

  94. Wilson SK, Carson CC, Cleves MA, et al. Quantifying risk of penile prosthesis infection with elevated glycosylated hemoglobin. J Urol. 1998;159:1537.

    CrossRef  CAS  PubMed  Google Scholar 

  95. Montague DK, Angermeier KW. Penile prosthesis implantation. Urol Clin North Am. 2001;28:355.

    CrossRef  CAS  PubMed  Google Scholar 

  96. Carson CC, Mulcahy JJ, Govier FE. Efficacy, safety and patient satisfaction outcomes of the AMS 700CX inflatable penile prosthesis: results of a long-term multicenter study. AMS 700CX study group. J Urol. 2000;164:376.

    CrossRef  CAS  PubMed  Google Scholar 

  97. Michal V, Kramar R, Pospichal J, et al. Direct arterial anastomosis on corpora cavernosa penis in the therapy of erective impotence. Rozhl Chir. 1973;52:587.

    CAS  PubMed  Google Scholar 

  98. Molodysky E, Liu SP, Huang SJ, et al. Penile vascular surgery for treating erectile dysfunction: current role and future direction. Arab J Urol. 2013;11:254.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  99. Kawanishi Y, Kimura K, Nakanishi R, et al. Penile revascularization surgery for arteriogenic erectile dysfunction: the long-term efficacy rate calculated by survival analysis. BJU Int. 2004;94:361.

    CrossRef  PubMed  Google Scholar 

  100. Munarriz R, Uberoi J, Fantini G, et al. Microvascular arterial bypass surgery: long-term outcomes using validated instruments. J Urol. 2009;182:643.

    CrossRef  PubMed  Google Scholar 

  101. Kayigil O, Okulu E, Aldemir M, et al. Penile revascularization in vasculogenic erectile dysfunction (ED): long-term follow-up. BJU Int. 2012;109:109.

    CrossRef  PubMed  Google Scholar 

  102. Wespes E, Schulman CC. Venous leakage: surgical treatment of a curable cause of impotence. J Urol. 1985;133:796.

    CrossRef  CAS  PubMed  Google Scholar 

  103. Vale JA, Feneley MR, Lees WR, et al. Venous leak surgery: long-term follow-up of patients undergoing excision and ligation of the deep dorsal vein of the penis. Br J Urol. 1995;76:192.

    CrossRef  CAS  PubMed  Google Scholar 

  104. Cakan M, Yalcinkaya F, Demirel F, et al. Is dorsale penile vein ligation (dpvl) still a treatment option in veno-occlusive dysfunction? Int Urol Nephrol. 2004;36:381.

    CrossRef  CAS  PubMed  Google Scholar 

  105. Hsu GL, Chen HS, Hsieh CH, et al. Clinical experience of a refined penile venous stripping surgery procedure for patients with erectile dysfunction: is it a viable option? J Androl. 2010;31:271.

    CrossRef  PubMed  Google Scholar 

  106. Hsu GL, Chen HS, Hsieh CH, et al. Salvaging penile venous stripping surgery. J Androl. 2010;31:250.

    CrossRef  PubMed  Google Scholar 

  107. Hsu GL, Chen HS, Hsieh CH, et al. Insufficient response to venous stripping surgery: is the penile vein recurrent or residual? J Androl. 2006;27:700.

    CrossRef  PubMed  Google Scholar 

  108. Hwang TI, Yang CR. Penile vein ligation for venogenic impotence. Eur Urol. 1994;26:46.

    CrossRef  CAS  PubMed  Google Scholar 

  109. Xu JK, Chen HJ, Li XD, et al. Optimal intensity shock wave promotes the adhesion and migration of rat osteoblasts via integrin beta1-mediated expression of phosphorylated focal adhesion kinase. J Biol Chem. 2012;287:26200.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  110. Liu T, Shindel AW, Lin G, et al. Cellular signaling pathways modulated by low-intensity extracorporeal shock wave therapy. Int J Impot Res. 2019;31:170.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  111. Rassweiler JJ, Knoll T, Kohrmann KU, et al. Shock wave technology and application: an update. Eur Urol. 2011;59:784.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  112. Wang CJ. An overview of shock wave therapy in musculoskeletal disorders. Chang Gung Med J. 2003;26:220.

    PubMed  Google Scholar 

  113. Vardi Y, Appel B, Kilchevsky A, et al. Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study. J Urol. 2012;187:1769.

    CrossRef  PubMed  Google Scholar 

  114. Olsen AB, Persiani M, Boie S, et al. Can low-intensity extracorporeal shockwave therapy improve erectile dysfunction? A prospective, randomized, double-blind, placebo-controlled study. Scand J Urol. 2015;49:329.

    CrossRef  PubMed  Google Scholar 

  115. Srini VS, Reddy RK, Shultz T, et al. Low intensity extracorporeal shockwave therapy for erectile dysfunction: a study in an Indian population. Can J Urol. 2015;22:7614.

    PubMed  Google Scholar 

  116. Kalyvianakis D, Hatzichristou D. Low-intensity shockwave therapy improves hemodynamic parameters in patients with vasculogenic erectile dysfunction: a triplex ultrasonography-based sham-controlled trial. J Sex Med. 2017;14:891.

    CrossRef  PubMed  Google Scholar 

  117. Sekiguchi H, Ii M, Losordo DW. The relative potency and safety of endothelial progenitor cells and unselected mononuclear cells for recovery from myocardial infarction and ischemia. J Cell Physiol. 2009;219:235.

    CrossRef  CAS  PubMed  Google Scholar 

  118. Takeuchi H, Natsume A, Wakabayashi T, et al. Intravenously transplanted human neural stem cells migrate to the injured spinal cord in adult mice in an SDF-1- and HGF-dependent manner. Neurosci Lett. 2007;426:69.

    CrossRef  CAS  PubMed  Google Scholar 

  119. Bahk JY, Jung JH, Han H, et al. Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: preliminary report of 7 cases. Exp Clin Transplant. 2010;8:150.

    PubMed  Google Scholar 

  120. Yiou R, Hamidou L, Birebent B, et al. Safety of intracavernous bone marrow-mononuclear cells for postradical prostatectomy erectile dysfunction: an open dose-escalation pilot study. Eur Urol. 2016;69:988.

    CrossRef  PubMed  Google Scholar 

  121. Haahr MK, Jensen CH, Toyserkani NM, et al. Safety and potential effect of a single intracavernous injection of autologous adipose-derived regenerative cells in patients with erectile dysfunction following radical prostatectomy: an open-label phase I clinical trial. EBioMedicine. 2016;5:204.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  122. Levy JA, Marchand M, Iorio L, et al. Determining the feasibility of managing erectile dysfunction in humans with placental-derived stem cells. J Am Osteopath Assoc. 2016;116:e1.

    PubMed  Google Scholar 

  123. Hall MP, Band PA, Meislin RJ, et al. Platelet-rich plasma: current concepts and application in sports medicine. J Am Acad Orthop Surg. 2009;17:602.

    CrossRef  PubMed  Google Scholar 

  124. Ding XG, Li SW, Zheng XM, et al. The effect of platelet-rich plasma on cavernous nerve regeneration in a rat model. Asian J Androl. 2009;11:215.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  125. Wu CC, Wu YN, Ho HO, et al. The neuroprotective effect of platelet-rich plasma on erectile function in bilateral cavernous nerve injury rat model. J Sex Med. 2012;9:2838.

    CrossRef  PubMed  Google Scholar 

  126. Scott S, Roberts M, Chung E. Platelet-rich plasma and treatment of erectile dysfunction: critical review of literature and global trends in platelet-rich plasma clinics. Sex Med Rev. 2019;7:306.

    CrossRef  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Columbia University Irving Medical Center, Department of Urology, New York, NY, USA

    Christopher I. Sayegh, Joseph M. Caputo, Vinson Wang & Denise Asafu-Adjei

Authors
  1. Christopher I. Sayegh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph M. Caputo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vinson Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Denise Asafu-Adjei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher I. Sayegh .

Editor information

Editors and Affiliations

  1. Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA

    MD Joseph P. Alukal

  2. Preston Robert Tisch Center, New York University, New York, NY, USA

    MD Steven Lamm

  3. University of Washington, Seattle, WA, USA

    MD Thomas J. Walsh

Rights and permissions

Reprints and Permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Sayegh, C.I., Caputo, J.M., Wang, V., Asafu-Adjei, D. (2021). Evaluation and Management of Erectile Dysfunction. In: Alukal, J.P., Lamm, S., Walsh, T.J. (eds) Design and Implementation of the Modern Men’s Health Center. Springer, Cham. https://doi.org/10.1007/978-3-030-54482-9_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-54482-9_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-54481-2

  • Online ISBN: 978-3-030-54482-9

  • eBook Packages: MedicineMedicine (R0)